Applied glycoproteomics-approaches to study genetic-environmental collisions causing protein-losing enteropathy

Biochimica et Biophysica Acta - General Subjects

Volumn 1760, Issue 4, 2006, Pages 547-559

  Bode, Lars ^a   Freeze, Hudson H ^a  

^a BURNHAM INSTITUTE   (United States)

Author keywords

Congenital disorder of glycosylation; Fontan surgery; Heart defect; Heparan sulfate; Protein losing enteropathy; TNF

Indexed keywords

CHROMIUM 51; CYTOKINE; GAMMA INTERFERON; GLYCOPROTEIN; HEPARAN SULFATE; HEPARIN; PROTEOHEPARAN SULFATE; TUMOR NECROSIS FACTOR ALPHA;

CLINICAL FEATURE; CONGENITAL DISORDER OF GLYCOSYLATION; CROHN DISEASE; DISEASE ASSOCIATION; DISEASE PREDISPOSITION; DRUG ACTIVITY; ELECTRIC RESISTANCE; FONTAN PROCEDURE; GENE EXPRESSION; GENETIC PREDISPOSITION; HUMAN; HYPERTENSION; INTESTINE EPITHELIUM CELL; ISOTOPE LABELING; MECHANOTRANSDUCTION; NONHUMAN; OSTEOPOROSIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOSING GASTROENTEROPATHY; PROTEOMICS; REPRODUCIBILITY; REVIEW; RISK ASSESSMENT; RISK FACTOR; TREATMENT OUTCOME;

ANIMALS; ENVIRONMENTAL EXPOSURE; GENETIC PREDISPOSITION TO DISEASE; GLYCOPROTEINS; HEPARAN SULFATE PROTEOGLYCANS; HUMANS; MICE; PROTEIN-LOSING ENTEROPATHIES; PROTEOMICS;

EID: 33646091745     PISSN: 03044165     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbagen.2005.11.004     Document Type: Review

References (88)

1. Beeken W.L., Busch H.J., and Sylwester D.L. Intestinal protein loss in Crohn's disease. Gastroenterology 62 (1972) 207-215
2. Martin J.A., Hamilton B.E., Sutton P.D., Ventura S.J., Menacker F., and Munson M.L. Births: final data for 2002. Natl. Vital Stat. Rep. 52 (2003) 1-113
3. Hoffman J.I., and Kaplan S. The incidence of congenital heart disease. J. Am. Coll. Cardiol. 39 (2002) 1890-1900
4. Mertens L., Hagler D.J., Sauer U., Somerville J., and Gewillig M. Protein-losing enteropathy after the Fontan operation: an international multicenter study. PLE study group. J. Thorac. Cardiovasc. Surg. 115 (1998) 1063-1073
5. Thorne S.A., Hooper J., Kemp M., and Somerville J. Gastro-intestinal protein loss in late survivors of Fontan surgery and other congenital heart disease. Eur. Heart J. 19 (1998) 514-520
6. Rychik J., and Spray T.L. Strategies to treat protein-losing enteropathy. Semin. Thorac. Cardiovasc. Surg., Pediatr. Card. Surg. Annu. 5 (2002) 3-11
7. Marino B.S. Outcomes after the Fontan procedure. Curr. Opin. Pediatr. 14 (2002) 620-626
8. Fujii T., Shimizu T., Takahashi K., Kishiro M., Ohkubo M., Akimoto K., and Yamashiro Y. Fecal alpha1-antitrypsin concentrations as a measure of enteric protein loss after modified Fontan operations. J. Pediatr. Gastroenterol. Nutr. 37 (2003) 577-580
9. Lenz D., Hambsch J., Schneider P., Hausler H.J., Sauer U., Hess J., and Tarnok A. Protein-losing enteropathy in patients with Fontan circulation: is it triggered by infection?. Crit. Care 7 (2003) 185-190
10. Shimizu T., Nagata S., Fujii T., Takahashi K., Kishiro M., Ohkubo M., Akimoto K., and Yamashiro Y. Enhanced production of interferon-gamma as a possible cause of protein-losing enteropathy after modified Fontan operation. J. Pediatr. Gastroenterol. Nutr. 37 (2003) 504-507
11. Ostrow A., and Rychik J. Possible mechanisms for development of protein-losing enteropathy after Fontan operation. J. Am. Coll. Cardiol. 43 suppl. A (2004) 397A
12. Bruewer M., Luegering A., Kucharzik T., Parkos C.A., Madara J.L., Hopkins A.M., and Nusrat A. Proinflammatory cytokines disrupt epithelial barrier function by apoptosis-independent mechanisms. J. Immunol. 171 (2003) 6164-6172
13. Chakravortty D., and Kumar K.S. Modulation of barrier function of small intestinal epithelial cells by lamina propria fibroblasts in response to lipopolysaccharide: possible role in TNFalpha in inducing barrier dysfunction. Microbiol. Immunol. 43 (1999) 527-533
14. Fink M.P. Intestinal epithelial hyperpermeability: update on the pathogenesis of gut mucosal barrier dysfunction in critical illness. Curr. Opin. Crit. Care 9 (2003) 143-151
15. Fish S.M., Proujansky R., and Reenstra W.W. Synergistic effects of interferon gamma and tumour necrosis factor alpha on T84 cell function. Gut 45 (1999) 191-198
16. Suenaert P., Bulteel V., Lemmens L., Noman M., Geypens B., Van Assche G., Geboes K., Ceuppens J.L., and Rutgeerts P. Anti-tumor necrosis factor treatment restores the gut barrier in Crohn's disease. Am. J. Gastroenterol. 97 (2002) 2000-2004
17. Madara J.L., and Stafford J. Interferon-gamma directly affects barrier function of cultured intestinal epithelial monolayers. J. Clin. Invest. 83 (1989) 724-727
18. Freeze H.H., and Aebi M. Altered glycan structures: the molecular basis of congenital disorders of glycosylation. Curr. Opin. Struct. Biol. 15 (2005) 490-498
19. Niehues R., Hasilik M., Alton G., Körner C., Schiebe-Sukumar M., Koch H.G., Zimmer K.P., Wu R., Harms E., Reiter K., von Figura K., Freeze H.H., Harms H.K., and Marquardt T. Carbohydrate-deficient glycoprotein syndrome type Ib. Phosphomannose isomerase deficiency and mannose therapy. J. Clin. Invest. 101 (1998) 1414-1420
20. Freeze H.H. Update and perspectives on congenital disorders of glycosylation. Glycobiology 11 (2001) 129R-143R
21. Harms H.K., Zimmer K.P., Kurnik K., Bertele-Harms R.M., Weidinger S., and Reiter K. Oral mannose therapy persistently corrects the severe clinical symptoms and biochemical abnormalities of phosphomannose isomerase deficiency. Acta Paediatr. 91 (2002) 1065-1072
22. Westphal V., Kjaergaard S., Davis J.A., Peterson S.M., Skovby F., and Freeze H.H. Genetic and metabolic analysis of the first adult with congenital disorder of glycosylation type ib: long-term outcome and effects of mannose supplementation. Mol. Genet. Metab. 73 (2001) 77-85
23. Westphal V., Murch S., Kim S., Srikrishna G., Winchester B., Day R., and Freeze H.H. Reduced heparan sulfate accumulation in enterocytes contributes to protein-losing enteropathy in a congenital disorder of glycosylation. Am. J. Pathol. 157 (2000) 1917-1925
24. Damen G., de Klerk H., Huijmans J., den Hollander J., and Sinaasappel M. Gastrointestinal and other clinical manifestations in 17 children with congenital disorders of glycosylation type Ia, Ib, and Ic. J. Pediatr. Gastroenterol. Nutr. 38 (2004) 282-287
25. Schollen E., Frank C.G., Keldermans L., Reyntjens R., Grubenmann C.E., Clayton P.T., Winchester B.G., Smeitink J., Wevers R.A., Aebi M., Hennet T., and Matthijs G. Clinical and molecular features of three patients with congenital disorders of glycosylation type Ih (CDG-Ih) (ALG8 deficiency). J. Med. Genet. 41 (2004) 550-556
26. Chantret I., Dancourt J., Dupre T., Delenda C., Bucher S., Vuillaumier-Barrot S., Ogier de Baulny H., Peletan C., Danos O., Seta N., Durand G., Oriol R., Codogno P., and Moore S.E. A deficiency in dolichyl-P-glucose:Glc1Man9GlcNAc2-PP-dolichyl alpha3-glucosyltransferase defines a new subtype of congenital disorders of glycosylation. J. Biol. Chem. 278 (2003) 9962-9971
27. Murch S.H., MacDonald T.T., Walker-Smith J.A., Levin M., Lionetti P., and Klein N.J. Disruption of sulphated glycosaminoglycans in intestinal inflammation. Lancet 341 (1993) 711-714
28. Kjellen L., and Lindahl U. Proteoglycans: structures and interactions. Annu. Rev. Biochem. 60 (1991) 443-475
29. Kanwar Y.S., Linker A., and Farquhar M.G. Increased permeability of the glomerular basement membrane to ferritin after removal of glycosaminoglycans (heparan sulfate) by enzyme digestion. J. Cell Biol 86 (1980) 688-693
30. Raats C.J., Van Den Born J., and Berden J.H. Glomerular heparan sulfate alterations: mechanisms and relevance for proteinuria. Kidney Int. 57 (2000) 385-400
31. Murch S.H., Winyard P.J., Koletzko S., Wehner B., Cheema H.A., Risdon R.A., Phillips A.D., Meadows N., Klein N.J., and Walker-Smith J.A. Congenital enterocyte heparan sulphate deficiency with massive albumin loss, secretory diarrhoea, and malnutrition. Lancet 347 (1996) 1299-1301
32. Rychik J. Management of protein-losing enteropathy after the Fontan procedure. Semin. Thorac. Cardiovasc. Surg., Pediatr. Card. Surg. Annu. 1 (1998) 15-22
33. Holmgren D., Berggren H., Wahlander H., Hallberg M., and Myrdal U. Reversal of protein-losing enteropathy in a child with Fontan circulation is correlated with central venous pressure after heart transplantation. Pediatr. Transplant. 5 (2001) 135-137
34. Sierra C., Calleja F., Picazo B., and Martinez-Valverde A. Protein-losing enteropathy secondary to Fontan procedure resolved after cardiac transplantation. J. Pediatr. Gastroenterol. Nutr. 24 (1997) 229-230
35. Kelly A.M., Feldt R.H., Driscoll D.J., and Danielson G.K. Use of heparin in the treatment of protein-losing enteropathy after Fontan operation for complex congenital heart disease. Mayo Clin. Proc. 73 (1998) 777-779
36. Donnelly J.P., Rosenthal A., Castle V.P., and Holmes R.D. Reversal of protein-losing enteropathy with heparin therapy in three patients with univentricular hearts and Fontan palliation. J. Pediatr. 130 (1997) 474-478
37. Neunlist M., Toumi F., Oreschkova T., Denis M., Leborgne J., Laboisse C.L., Galmiche J.P., and Jarry A. Human ENS regulates the intestinal epithelial barrier permeability and a tight junction-associated protein ZO-1 via VIPergic pathways. Am. J. Physiol.: Gastrointest. Liver Physiol. 285 (2003) G1028-G1036
38. Resta-Lenert S., and Barrett K.E. Live probiotics protect intestinal epithelial cells from the effects of infection with enteroinvasive Escherichia coli (EIEC). Gut 52 (2003) 988-997
39. Schmitz H., Fromm M., Bentzel C.J., Scholz P., Detjen K., Mankertz J., Bode H., Epple H.J., Riecken E.O., and Schulzke J.D. Tumor necrosis factor-alpha (TNFalpha) regulates the epithelial barrier in the human intestinal cell line HT-29/B6. J. Cell Sci. 112 Pt. 1 (1999) 137-146
40. Stoeltzing O., Ahmad S.A., Liu W., McCarty M.F., Wey J.S., Parikh A.A., Fan F., Reinmuth N., Kawaguchi M., Bucana C.D., and Ellis L.M. Angiopoietin-1 inhibits vascular permeability, angiogenesis, and growth of hepatic colon cancer tumors. Cancer Res. 63 (2003) 3370-3377
41. Massey-Harroche D. Epithelial cell polarity as reflected in enterocytes. Microsc. Res. Tech. 49 (2000) 353-362
42. Bode L., Eklund E.A., Murch S., and Freeze H.H. Heparan sulfate depletion amplifies TNF-alpha-induced protein leakage in an in vitro model of protein-losing enteropathy. Am. J. Physiol.: Gastrointest. Liver Physiol. 288 (2005) G1015-G1023
43. Ramasamy S., Lipke D.W., McClain C.J., and Hennig B. Tumor necrosis factor reduces proteoglycan synthesis in cultured endothelial cells. J. Cell. Physiol. 162 (1995) 119-126
44. Endo K., Takino T., Miyamori H., Kinsen H., Yoshizaki T., Furukawa M., and Sato H. Cleavage of syndecan-1 by membrane type matrix metalloproteinase-1 stimulates cell migration. J. Biol. Chem. 278 (2003) 40764-40770
45. Ma T.Y., Iwamoto G.K., Hoa N.T., Akotia V., Pedram A., Boivin M.A., and Said H.M. TNF-alpha-induced increase in intestinal epithelial tight junction permeability requires NF-kappa B activation. Am. J. Physiol.: Gasterointest. Liver Physiol. 286 (2004) G367-G376
46. Mitic L.L., and Anderson J.M. Molecular architecture of tight junctions. Annu. Rev. Physiol. 60 (1998) 121-142
47. Mankertz J., Tavalali S., Schmitz H., Mankertz A., Riecken E.O., Fromm M., and Schulzke J.D. Expression from the human occludin promoter is affected by tumor necrosis factor alpha and interferon gamma. J. Cell Sci. 113 (2000) 2085-2090
48. Chen G., and Goeddel D.V. TNF-R1 signaling: a beautiful pathway. Science 296 (2002) 1634-1635
49. Watson A.J., Chu S., Sieck L., Gerasimenko O., Bullen T., Campbell F., McKenna M., Rose T., and Montrose M.H. Epithelial barrier function in vivo is sustained despite gaps in epithelial layers. Gastroenterology 129 (2005) 902-912
50. Prasad S., Mingrino R., Kaukinen K., Hayes K.L., Powell R.M., Macdonald T.T., and Collins J.E. Inflammatory processes have differential effects on claudins 2, 3 and 4 in colonic epithelial cells. Lab. Invest. 85 (2005) 1139-1162
51. Tsujimoto M., and Vilcek J. Tumor necrosis factor receptors in HeLa cells and their regulation by interferon-gamma. J. Biol. Chem. 261 (1986) 5384-5388
52. Tsujimoto M., Feinman R., and Vilcek J. Differential effects of type I IFN and IFN-gamma on the binding of tumor necrosis factor to receptors in two human cell lines. J. Immunol. 137 (1986) 2272-2276
53. Petitou M., Casu B., and Lindahl U. 1976-1983, a critical period in the history of heparin: the discovery of the antithrombin binding site. Biochimie 85 (2003) 83-89
54. Bendayan I., and Casaldaliga J. Protein-losing enteropathy. Pediatr. Cardiol. 23 (2002) 249
55. Lortat-Jacob H., and Grimaud J.A. Interferon-gamma C-terminal function: new working hypothesis. Heparan sulfate and heparin, new targets for IFN-gamma, protect, relax the cytokine and regulate its activity. Cell. Mol. Biol. 37 (1991) 253-260
56. Lortat-Jacob H., and Grimaud J.A. Interferon-gamma binds to heparan sulfate by a cluster of amino acids located in the C-terminal part of the molecule. FEBS Lett. 280 (1991) 152-154
57. Harvima I.T., Lappalainen K., Hirvonen M.R., Matto M., Kivinen P.K., Hyttinen M., Pelkonen J., and Naukkarinen A. Heparin modulates the growth and adherence and augments the growth-inhibitory action of TNF-alpha on cultured human keratinocytes. J. Cell. Biochem. 92 (2004) 372-386
58. Lantz M., Thysell H., Nilsson E., and Olsson I. On the binding of tumor necrosis factor (TNF) to heparin and the release in vivo of the TNF-binding protein I by heparin. J. Clin. Invest. 88 (1991) 2026-2031
59. Sadir R., Forest E., and Lortat-Jacob H. The heparan sulfate binding sequence of interferon-gamma increased the on rate of the interferon-gamma-interferon-gamma receptor complex formation. J. Biol. Chem. 273 (1998) 10919-10925
60. Lortat-Jacob H., Turnbull J.E., and Grimaud J.A. Molecular organization of the interferon gamma-binding domain in heparan sulphate. Biochem. J. 310 (1995) 497-505
61. Sarrazin S., Bonnaffe D., Lubineau A., and Lortat-Jacob H. Heparan sulfate mimicry: a synthetic glycoconjugate that recognizes the heparin-binding domain of IFNgamma inhibits the cytokine activity. J. Biol. Chem. 280 45 (2005) 37558-37564
62. Grobe K., Ledin J., Ringvall M., Holmborn K., Forsberg E., Esko J.D., and Kjellen L. Heparan sulfate and development: differential roles of the N-acetylglucosamine N-deacetylase/N-sulfotransferase isozymes. Biochim. Biophys. Acta 1573 (2002) 209-215
63. Morimoto-Tomita M., Uchimura K., Werb Z., Hemmerich S., and Rosen S.D. Cloning and characterization of two extracellular heparin-degrading endosulfatases in mice and humans. J. Biol. Chem. 277 (2002) 49175-49185
64. Tveit H., Dick G., Skibeli V., and Prydz K. A proteoglycan undergoes different modifications en route to the apical and basolateral surfaces of Madin-Darby canine kidney cells. J. Biol. Chem. 280 (2005) 29596-29603
65. Carter N.M., Ali S., and Kirby J.A. Endothelial inflammation: the role of differential expression of N-deacetylase/N-sulphotransferase enzymes in alteration of the immunological properties of heparan sulphate. J. Cell Sci. 116 (2003) 3591-3600
66. Kjellen L. Glucosaminyl N-deacetylase/N-sulphotransferases in heparan sulphate biosynthesis and biology. Biochem. Soc. Trans. 31 (2003) 340-342
67. Szabo S., Kusstatscher S., Sakoulas G., Sandor Z., Vincze A., and Jadus M. Growth factors: new 'endogenous drugs' for ulcer healing. Scandinavian Journal of Gastroenterology-Supplement 210 (1995) 15-18
68. Klagsbrun M., and Baird A. A dual receptor system is required for basic fibroblast growth factor activity. Cell 67 (1991) 229-231
69. Yayon A., Klagsbrun M., Esko J.D., Leder P., and Ornitz D.M. Cell surface, heparin-like molecules are required for binding of basic fibroblast growth factor to its high affinity receptor. Cell 64 (1991) 841-848
70. Day R., and Forbes A. Heparin, cell adhesion, and pathogenesis of inflammatory bowel disease. Lancet 354 (1999) 62-65
71. Quigley E.M., Ross I.N., Haeney M.R., Holbrook I.B., and Marsh M.N. Reassessment of faecal alpha-1-antitrypsin excretion for use as screening test for intestinal protein loss. J. Clin. Pathol. 40 (1987) 61-66
72. Crossley J.R., and Elliott R.B. Simple method for diagnosing protein-losing enteropathies. Br. Med. J. 1 (1977) 428-429
73. Olson N.C., and Zimmer J.F. Protein-losing enteropathy secondary to intestinal lymphangiectasia in a dog. J. Am. Vet. Med. Assoc. 173 (1978) 271-274
74. King C.E., and Toskes P.P. Protein-losing enteropathy in the human and experimental rat blind-loop syndrome. Gastroenterology 80 (1981) 504-509
75. Kitagawa H., Ford E.G., Sinatra F., Thomas D., and Atkinson J.B. Fecal fat, cyclosporine, and alpha 1-antitrypsin for assessment of small bowel function following transplantation. J. Pediatr. Surg. 26 (1991) 1091-1095 (discussion 1095-6)
76. Patton J.S., Peters P.M., McCabe J., Crase D., Hansen S., Chen A.B., and Liggitt D. Development of partial tolerance to the gastrointestinal effects of high doses of recombinant tumor necrosis factor-alpha in rodents. J. Clin. Invest. 80 (1987) 1587-1596
77. Lin X., Wei G., Shi Z., Dryer L., Esko J.D., Wells D.E., and Matzuk M.M. Disruption of gastrulation and heparan sulfate biosynthesis in EXT1-deficient mice. Dev. Biol. 224 (2000) 299-311
78. Inatani M., Irie F., Plump A.S., Tessier-Lavigne M., and Yamaguchi Y. Mammalian brain morphogenesis and midline axon guidance require heparan sulfate. Science 302 (2003) 1044-1046
79. Madison B.B., Dunbar L., Qiao X.T., Braunstein K., Braunstein E., and Gumucio D.L. Cis elements of the villin gene control expression in restricted domains of the vertical (crypt) and horizontal (duodenum, cecum) axes of the intestine. J. Biol. Chem. 277 (2002) 33275-33283
80. Zcharia E., Metzger S., Chajek-Shaul T., Aingorn H., Elkin M., Friedmann Y., Weinstein T., Li J.P., Lindahl U., and Vlodavsky I. Transgenic expression of mammalian heparanase uncovers physiological functions of heparan sulfate in tissue morphogenesis, vascularization, and feeding behavior. FASEB J. 18 (2004) 252-263
81. Alexander C.M., Reichsman F., Hinkes M.T., Lincecum J., Becker K.A., Cumberledge S., and Bernfield M. Syndecan-1 is required for Wnt-1-induced mammary tumorigenesis in mice. Nat. Genet. 25 (2000) 329-332
82. Gotte M., Joussen A.M., Klein C., Andre P., Wagner D.D., Hinkes M.T., Kirchhof B., Adamis A.P., and Bernfield M. Role of syndecan-1 in leukocyte-endothelial interactions in the ocular vasculature. Invest. Ophthalmol. Visual Sci. 43 (2002) 1135-1141
83. C. Derossi, L. Bode, E.A Eklund, F. Zhang, J.A. Davis, V. Westphal, L. Wang, A. Borowsk, H.H. Freeze, Ablation of mouse phosphomannose isomerase (Mpi) causes mannose-6-phosphate accumulation, toxicity, and embryonic lethality, J. Biol. Chem. (in press).
84. Freeze H.H., and Westphal V. Balancing N-linked glycosylation to avoid disease. Biochimie 83 (2001) 791-799
85. Ingber D.E. Tensegrity: the architectural basis of cellular mechanotransduction. Annu. Rev. Physiol. 59 (1997) 575-599
86. Ingber D.E. Integrins, tensegrity, and mechanotransduction. Gravit. Space Biol. Bull.: Publ. Am. Soc. Gravit. Space Biol. 10 (1997) 49-55
87. Al-Jamal R., and Ludwig M.S. Changes in proteoglycans and lung tissue mechanics during excessive mechanical ventilation in rats. Am. J. Physiol., Lung Cell. Mol. Physiol. 281 (2001) L1078-L1087
88. Sasamura H., Shimizu-Hirota R., Nakaya H., and Saruta T. Effects of AT1 receptor antagonist on proteoglycan gene expression in hypertensive rats. Hypertens. Res.-Clin. Exp. 24 (2001) 165-172